LAVAL, QC, Dec. 30, 2020
/CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch
Health"), today announced that the Office for Registration of
Medicinal Products, Medical Devices and Biocidal Products in
Poland has granted an additional
new indication for DEXAVEN (dexamethasone phosphate) solution for
injection, 4 mg/ml, for the treatment of COVID-19 in adult and
adolescent patients (12 years of age and older weighing at least 40
kg) who require oxygen therapy. DEXAVEN is a corticosteroid that
reduces inflammation.
"We're pleased that Poland's
Office for Registration of Medicinal Products, Medical Devices and
Biocidal Products has approved DEXAVEN for the treatment of
symptoms due to COVID-19, because now patients in Poland have another treatment option to fight
this virus," said Thomas J. Appio,
president, Bausch + Lomb/International, Bausch Health. "Bausch
Health continues to evaluate our health care products and medicines
around the world to determine if they may offer valuable treatment
options for COVID-19, and we will continue to do what we can to
assist in the global efforts to end the pandemic."
Dexamethasone-containing products in the United States are not approved as a
treatment for COVID-19 by the U.S. Food and Drug
Administration. Patients should only use these products in
accordance with their approved label and the directions of their
doctor.
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company
whose mission is to improve people's lives with our health care
products. We develop, manufacture and market a range of
pharmaceutical, medical device and over-the-counter products,
primarily in the therapeutic areas of eye health, gastroenterology
and dermatology. We are delivering on our commitments as we build
an innovative company dedicated to advancing global health. More
information can be found at www.bauschhealth.com.
Forward-looking Statements
This news release may contain forward-looking statements, which
may generally be identified by the use of the words "anticipates,"
"expects," "intends," "plans," "should," "could," "would," "may,"
"believes," "estimates," "potential," "target," or "continue" and
variations or similar expressions. These statements are based upon
the current expectations and beliefs of management and are subject
to certain risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, the risks and uncertainties discussed in the Bausch
Health's most recent annual report on Form 10-K and detailed from
time to time in Bausch Health's other filings with the U.S.
Securities and Exchange Commission and the Canadian Securities
Administrators, which factors are incorporated herein by reference.
They also include, but are not limited to, risks and uncertainties
caused by or relating to the evolving COVID-19 pandemic, and the
fear of that pandemic and its potential effects, the severity,
duration and future impact of which are highly uncertain and cannot
be predicted, and which may have a material adverse impact on
Bausch Health, including but not limited to its project development
timelines, and costs (which may increase). Readers are cautioned
not to place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of the
date hereof. Bausch Health undertakes no obligation to update any
of these forward-looking statements to reflect events or
circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
Investor
Contact:
|
Media
Contact:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@bauschhealth.com
|
lainie.keller@bauschhealth.com
|
(514)
856-3855
|
(908)
927-1198
|
(877) 281-6642 (toll
free)
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bausch-healths-dexaven-dexamethasone-phosphate-receives-new-indication-in-poland-to-treat-patients-with-sars-cov-2-covid-19-301199175.html
SOURCE Bausch Health Companies Inc.